Abstract:ABSTRACT The current treatments for toxoplasmosis are only active against fast-growing tachyzoites, present in acute infections, with little effect on slow-growing bradyzoites within tissue cysts, present in latent chronic infections. The mitochondrion of Toxoplasma gondii is essential for its survival, and one of the major anti-parasitic drugs, atovaquone, inhibits the mitochondrial electron transport chain at the coenzyme Q:cytochrome c oxidoreductase site. Coenzyme Q (also known as ubiquinone [UQ]) consists of a quinone head and a lipophilic, isoprenoid tail that anchors UQ to membranes. The synthesis of the isoprenoid unit is essential for cell growth and is inhibited by lipophilic bisphosphonates, which inhibit the parasite growth. In this work, we investigated the effect of lipophilic bisphosphonates on the chronic stages of T. gondii . We discovered that three lipophilic bisphosphonates (BPH-1218, BPH-1236, and BPH-1238), effective for the acute infection, were also effective in controlling the development of chronic stages. We showed effectiveness by testing them against in vitro cysts and in vivo derived tissue cysts and, most importantly, these compounds reduced the cyst burden in the brains of chronically infected mice. We monitored the activity of infected mice non-invasively and continuously with a novel device termed the CageDot. A decrease in activity accompanied the acute phase, but mice recovered to normal activity and showed signs of hyperactivity when the chronic infection was established. Moreover, treatment with atovaquone or BPH-1218 ameliorated the hyperactivity observed during the chronic infection. IMPORTANCE Treatment for toxoplasmosis is challenged by a lack of effective drugs to eradicate the chronic stages. Most of the drugs currently used are poorly distributed to the central nervous system, and they trigger allergic reactions in a large number of patients. There is a compelling need for safe and effective treatments for toxoplasmosis. Bisphosphonates (BPs) are analogs of inorganic pyrophosphate and are used for the treatment of bone disorders. BPs target the isoprenoid pathway and are effective against several experimental parasitic infections. Some lipophilic BPs can specifically inhibit the mitochondrial activity of Toxoplasma gondii by interfering with the mechanism by which ubiquinone is inserted into the inner mitochondrial membrane. In this work, we present the effect of three lipophilic BPs against T. gondii chronic stages. We also present a new strategy for the monitoring of animal activity during disease and treatment that is non-invasive and continuous.

Anti- Toxoplasma gondii&nbsp;effect of Lumefantrine in vitro and in vivo

Determination of Lumefantrine As an Effective Drug Against Toxoplasma Gondii Infection – in Vitro and in Vivo Study

A Metabolomic and Transcriptomic Study Revealed the Mechanisms of Lumefantrine Inhibition of Toxoplasma gondii

Synthesis, in Vitro and in Vivo Biological Evaluation of Dihydroartemisinin Derivatives with Potential Anti-Toxoplasma Gondii Agents.

In Vitro Evaluation Reveals Effect and Mechanism of Artemether against Toxoplasma gondii

Effect of Changqing Capsule on Toxoplasma Gondii Tachyzoites As Demonstrated by Ultrastructual Studies

A Long-Lasting Protective Immunity Against Chronic Toxoplasmosis in Mice Induced by Recombinant Rhoptry Proteins Encapsulated in Poly (Lactide-Co-glycolide) Microparticles.

Evaluation of Potential Anti-Toxoplasmosis Efficiency of Combined Traditional Herbs in a Mouse Model

Effectiveness of Miltefosine Nanoemulsion Concerning the Treatment of Acute and Chronic Toxoplasmosis: In Vivo Study

Chemotherapeutics for Toxoplasma gondii : Molecular Biotargets, Binding Modes, and Structure–Activity Relationship Investigations

Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma Gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS

Anti-Toxoplasma gondii effects of XYP1-derived peptides and regulatory mechanisms of XYP1

Lipophilic bisphosphonates reduced cyst burden and ameliorated hyperactivity of mice chronically infected with Toxoplasma gondii

Synthesis of ferrocenyl benzimidazole derivatives as novel anti- Toxoplasma gondii agents

Triclabendazole and clofazimine reduce replication and spermine uptake in vitro in Toxoplasma gondii

Could Metformin Modulate the Outcome of Chronic Murine Toxoplasmosis?

Anti-Toxoplasma gondii effect of tylosin in vitro and in vivo

In vitro anti-Toxoplasma gondii effects of a coccidiostat dinitolmide

Tylvalosin demonstrates anti-parasitic activity and protects mice from acute toxoplasmosis

High Throughput Repurposing Screen Reveals Compounds with Activity Against Toxoplasma gondii Bradyzoites

Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model

Anti- Toxoplasma gondii&amp;nbsp;effect of Lumefantrine in vitro and in vivo